The observed association between TNF-α antagonists and increased TB risk highlights the necessity of TB screening and vigilant monitoring, especially for patients testing negative on IGRA or TST who may not receive preventive therapy [[78], [79], [80], [81]]. The gene discussed is TNF; the disease is tuberculosis.